243 related articles for article (PubMed ID: 29404935)
1. The Effect of Obesity on Anti-Xa Concentrations in Bariatric Patients.
Schijns W; Deenen MJ; Aarts EO; Homan J; Janssen IMC; Berends FJ; Kaasjager KAH
Obes Surg; 2018 Jul; 28(7):1997-2005. PubMed ID: 29404935
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint.
Diepstraten J; Janssen EJ; Hackeng CM; van Dongen EP; Wiezer RJ; van Ramshorst B; Knibbe CA
Eur J Clin Pharmacol; 2015 Jan; 71(1):25-34. PubMed ID: 25304008
[TBL] [Abstract][Full Text] [Related]
3. Lean body weight is the best scale for venous thromboprophylaxis algorithm in severely obese patients undergoing bariatric surgery.
Gaborit B; Moulin PA; Bege T; Boullu S; Vincentelli C; Emungania O; Morange PE; Berdah S; Salem JE; Dutour A; Frere C
Pharmacol Res; 2018 May; 131():211-217. PubMed ID: 29452290
[TBL] [Abstract][Full Text] [Related]
4. Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial.
Kalfarentzos F; Stavropoulou F; Yarmenitis S; Kehagias I; Karamesini M; Dimitrakopoulos A; Maniati A
Obes Surg; 2001 Dec; 11(6):670-6. PubMed ID: 11775562
[TBL] [Abstract][Full Text] [Related]
5. Fixed-dose enoxaparin after bariatric surgery: the influence of body weight on peak anti-Xa levels.
Celik F; Huitema AD; Hooijberg JH; van de Laar AW; Brandjes DP; Gerdes VE
Obes Surg; 2015 Apr; 25(4):628-34. PubMed ID: 25223871
[TBL] [Abstract][Full Text] [Related]
6. Impact of Weight on Anti-Xa Attainment in High-Risk Trauma Patients on Enoxaparin Chemoprophylaxis.
Farrar JE; Droege ME; Philpott CD; Mueller EW; Ernst NE; Makley AT; Deichstetter KM; Droege CA
J Surg Res; 2021 Aug; 264():425-434. PubMed ID: 33848842
[TBL] [Abstract][Full Text] [Related]
7. A New Protocol for Venous Thromboembolism Prophylaxis in Bariatric Surgery.
Abuoglu HH; Müftüoğlu MAT; Odabaşı M
Obes Surg; 2019 Feb; 29(2):729-734. PubMed ID: 30542826
[TBL] [Abstract][Full Text] [Related]
8. Extended use of bemiparin as thromboprophylaxis during bariatric surgery: results of anti-factor Xa activity measurements.
Muñoz-Atienza V; Gil-Rendo A; Amo-Salas M; Núñez-Guerrero P; Martín-Fernández J
Surg Obes Relat Dis; 2018 Mar; 14(3):354-360. PubMed ID: 29361459
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic Comparison of Subcutaneous and Intravenous Nadroparin Administration for Thromboprophylaxis in Critically Ill Patients on Vasopressors.
Cihlar R; Sramek V; Papiez A; Penka M; Suk P
Pharmacology; 2020; 105(1-2):73-78. PubMed ID: 31578015
[TBL] [Abstract][Full Text] [Related]
10. Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity.
Borkgren-Okonek MJ; Hart RW; Pantano JE; Rantis PC; Guske PJ; Kane JM; Gordon N; Sambol NC
Surg Obes Relat Dis; 2008; 4(5):625-31. PubMed ID: 18261965
[TBL] [Abstract][Full Text] [Related]
11. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin).
Mismetti P; Laporte-Simitsidis S; Navarro C; Sié P; d'Azemar P; Necciari J; Duret JP; Gaud C; Decousus H; Boneu B
Thromb Haemost; 1998 Jun; 79(6):1162-5. PubMed ID: 9657442
[TBL] [Abstract][Full Text] [Related]
12. Supraprophylactic Anti-Factor Xa Levels Are Associated with Major Bleeding in Neurosurgery Patients Receiving Prophylactic Enoxaparin.
May CC; Cua S; Smetana KS; Powers CJ
World Neurosurg; 2022 Jan; 157():e357-e363. PubMed ID: 34655821
[TBL] [Abstract][Full Text] [Related]
13. Prophylaxis of thromboembolism in bariatric surgery with parnaparin.
Forestieri P; Quarto G; De Caterina M; Cuocolo A; Pilone V; Formato A; Ruocco A; Ferrari P
Obes Surg; 2007 Dec; 17(12):1558-62. PubMed ID: 18004632
[TBL] [Abstract][Full Text] [Related]
14. Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study.
Steib A; Degirmenci SE; Junke E; Asehnoune K; Figier M; Pericard C; Rohr S; Letessier E; Brunaud L; Vix M; Zobairi F; Grunebaum L; Toti F
Surg Obes Relat Dis; 2016; 12(3):613-621. PubMed ID: 26686309
[TBL] [Abstract][Full Text] [Related]
15. No accumulation of a prophylactic dose of nadroparin in moderate renal insufficiency.
Atiq F; van den Bemt PM; Leebeek FW; van Gelder T; Versmissen J
Neth J Med; 2015 Oct; 73(8):373-8. PubMed ID: 26478547
[TBL] [Abstract][Full Text] [Related]
16. Anti-Xa Levels 4 h After Subcutaneous Administration of 5,700 IU Nadroparin Strongly Correlate with Lean Body Weight in Morbidly Obese Patients.
Diepstraten J; Hackeng CM; van Kralingen S; Zapletal J; van Dongen EP; Wiezer RJ; van Ramshorst B; Knibbe CA
Obes Surg; 2012 Feb; ():. PubMed ID: 22302439
[TBL] [Abstract][Full Text] [Related]
17. Enoxaparin dosing after cesarean delivery in morbidly obese women.
Overcash RT; Somers AT; LaCoursiere DY
Obstet Gynecol; 2015 Jun; 125(6):1371-1376. PubMed ID: 26000508
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study).
Imberti D; Legnani C; Baldini E; Cini M; Nicolini A; Guerra M; De Paoli M; Zanardi A; Palareti G
Thromb Res; 2009 Dec; 124(6):667-71. PubMed ID: 19482341
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamics and tolerance of two nadroparin formulations (10,250 and 20,500 anti Xa IU x ml(-1)) delivered for 10 days at therapeutic dose.
Boneu B; Navarro C; Cambus JP; Caplain H; d'Azemar P; Necciari J; Duret JP; Gaud C; Sié P
Thromb Haemost; 1998 Feb; 79(2):338-41. PubMed ID: 9493587
[TBL] [Abstract][Full Text] [Related]
20. Effect of prophylactic dalteparin on anti-factor Xa levels in morbidly obese patients after bariatric surgery.
Simoneau MD; Vachon A; Picard F
Obes Surg; 2010 Apr; 20(4):487-91. PubMed ID: 18931882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
